NCT04092595View on ClinicalTrials.gov

A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

January 15, 2020

Study Completion Date

January 15, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

PF-06651600

PF-06651600: 200 mg dose provided as four 50 mg oral tablets

DRUG

Rosuvastatin

10 mg oral tablet

Trial Locations (1)

B-1070

Brussels Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04092595 - A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants | Biotech Hunter | Biotech Hunter